Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493502 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT04493502 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04493502, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3041658
Study Locations (20)
Florida
- Skin Care Research, Inc - Hollywood
- Nova Clinical Research, LLC - Miami
- ForCare Clinical Research - Tampa
California
- First OC Dermatology - Fountain Valley
- Dermatology Research Associates - Los Angeles
Georgia
- Marietta Dermatology Clinical Research - Marietta
- Advanced Medical Research - Sandy Springs
Massachusetts
- Allcutis Research, Inc. - Beverly
- Beth Israel Deaconess Medical Center - Boston
Ohio
- UC Physicians Office Dermatology - Cincinnati
- University Hospitals Case Medical Center - Cleveland
Arkansas
- Northwest Arkansas Clinical Trials Center - Rogers
Missouri
- Washington University School of Medicine - St Louis
New Hampshire
- ALLCUTIS Research - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493502
The ClinicalTrials.gov registry entry for NCT04493502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (88% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04493502 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04493502 about?
NCT04493502 is a clinical study titled "A Study of LY3041658 in Adults With Hidradenitis Suppurativa". The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
What is the current status of trial NCT04493502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2020-08-26. Estimated completion is 2022-10-13.
What conditions does trial NCT04493502 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT04493502?
The interventions under investigation include: Placebo (DRUG), LY3041658 (DRUG).
Who is sponsoring clinical trial NCT04493502?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04493502 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.